Bacterial in-fighting provides new treatment for hospital infections
A bacteria that is a leading cause of death worldwide from hospital acquired infections following antibiotic treatment looks set to be brought down through its own sibling rivalry.
The team of scientists from the University of Sheffield, the California-based biotech company, AvidBiotics Corp, and the University of Glasgow also found that, when C. diff develops a resistance to these weapons, the bacteria can no longer cause infection, making them harmless.
The research is published in Science Translational Medicine.
C. diff lives in the human gut – usually in small numbers – but when people take antibiotics, this kills off many of their protective gut bacteria, allowing C. diff to get a stronger foothold. It then grows very quickly, releasing toxins that cause diarrhoea and inflammation which can be fatal.
Like many bacteria, C. diff can make a weapon that is able to identify and kill competing C. diff strains. This weapon attaches to the surface of other C. diff cells and fires a harpoon-type needle through their membrane, causing the cell to die.
Scientists from AvidBiotics Corp have managed to engineer this weapon so that it can be mass produced in a stable form as a potential treatment or preventative for C. diff infections.
But although this set of antimicrobial agents, called Avidocin-CDs, can kill multiple strains of C. diff without impacting other ‘friendly’ bacteria, they were still unsure exactly how these ‘weapons’ identified the different strains of C. diff and why other bacteria were left unharmed.
So they teamed up with Dr Robert Fagan from the University of Sheffield’s Department of Molecular Biology and Biotechnology, who is an expert in the crystalline outer layer of C. difficile, known as the S-layer. The team realised that the answer seemed to be linked to different types of S-layer – C. diff strains produce one of 14 possible different types.
Dr Fagan said: “We discovered that the weapons naturally produced by C. diff and those engineered by our colleagues at AvidBiotics were using certain proteins in the S-layer to identify which strains to target. The C. diff S-layer is unique to these bacteria, which explains why Avidocin-CD killing is so specific. Scientists at AvidBiotics Corp were then able to engineer different versions of Avidocin-CD to target 12 of the 14 known types of S-layer.”
Moreover, the team also discovered that by getting rid of its S-layer, C. diff could become resistant to the weapons, but it was then no longer able to produce large quantities of toxin. Dr Gillian Douce at the University of Glasgow was able to show that while these resistant C. diff could still survive and multiply in the gut, they became harmless and no longer caused disease.
The research has so far only been carried out in the laboratory and in animal studies, so further work will be needed before the treatment can be made available in the clinic.
Full paper details
New Class of Precision Antimicrobials Redefines Role of Clostridium difficile S-layer in Virulence and Viability’ by Joseph A. Kirk, Dana Gebhart, Anthony M. Buckley, Stephen Lok, Dean Scholl, Gillian R. Douce, Gregory R. Govoni, Robert P. Fagan is published in Science Translational Medicine:
For further information please contact:
Media Relations Officer
University of Sheffield
0114 222 9859